Table 1.
Baseline characteristics of study population (n=333).
| Age at Diagnosis (years) | Group A < 55 | Group B 55 - 64 | Group C 65 - 74 | Group D ≥ 75 | Total |
|---|---|---|---|---|---|
| n (%) | 30 (9%) | 124 (37%) | 145 (43%) | 35 (10%) | 333(100%) |
| Characteristics at Time of Diagnosis | |||||
| Stage at Dx† | |||||
| 1-2 | 4 (14%) | 19 (17%) | 40 (31%) | 7 (21%) | 70 (23%) |
| 3 | 5 (17%) | 38 (34%) | 35 (27%) | 8 (24%) | 86 (29%) |
| 4 | 20 (69%) | 54 (49%) | 53 (41%) | 18 (55%) | 145 (48%) |
| PSA at Dx | |||||
| 0 - <10 | 10 (40%) | 23 (23%) | 31 (28%) | 6 (18%) | 70 (26%) |
| 10 - <20 | 2 (8%) | 22 (22%) | 24 (21%) | 2 (6%) | 50 (18%) |
| 20 - <100 | 7 (28%) | 34 (34%) | 33 (34%) | 11 (33%) | 90 (33%) |
| ≥100 | 6 (24%) | 22 (22%) | 19 (17%) | 14 (42%) | 61 (23%) |
| Prostatectomy at Dx† | |||||
| No | 24 (80%) | 94 (77%) | 120 (83%) | 34 (97%) | 272 (82%) |
| Yes | 6 (20%) | 28 (23%) | 24 (17%) | 1 (3%) | 59 (18%) |
| RT at Dx | |||||
| No | 19 (63%) | 80 (66%) | 89 (62%) | 28 (80%) | 216 (65%) |
| Yes | 11 (37%) | 42 (35%) | 55 (38%) | 7 (20%) | 115 (35%) |
| Gleason at Dx | |||||
| <=6 | 2 (7%) | 6 (6%) | 14 (11%) | 3 (11%) | 25 (9%) |
| 7 | 8 (30%) | 34 (33%) | 40 (33%) | 5 (18%) | 87 (31%) |
| 8-10 | 17 (63%) | 63 (61%) | 68 (56%) | 20 (71%) | 168 (60%) |
| CCI at time of Dx† | |||||
| 0 | 22 (73%) | 59 (50%) | 56 (40%) | 8 (25%) | 145 (45%) |
| 1-2 | 7 (23%) | 46 (39%) | 66 (47%) | 16 (50%) | 135 (42%) |
| 3-4 | 1 (3%) | 9 (8%) | 14 (10%) | 8 (25%) | 32 (10%) |
| >4 | 0 (0%) | 4 (3%) | 3 (2%) | 0 (0%) | 7 (2%) |
| Time in Years to Bone Mets or Death from Dx | |||||
| (median) † | 1.15 | 3.95 | 4.07 | 2.08 | 3.44 |
| Characteristics at Time of CRPC | |||||
| PSA Nadir on ADT† | |||||
| <4 | 19 (63%) | 85 (79%) | 92 (75%) | 18 (56%) | 214 (73%) |
| ≥4 | 11 (37%) | 23 (21%) | 31 (25%) | 14 (44%) | 79 (27%) |
| Time in Months to PSA Nadir from ADT Initiation (mean) † | 22.5 | 19.6 | 21.5 | 9.21 | 20.0 |
| Visceral Disease | |||||
| No | 21 (70%) | 101 (82%) | 125 (86%) | 30 (86%) | 277 (83%) |
| Yes | 9 (30%) | 22 (18%) | 20 (14%) | 5 (14%) | 56 (17%) |
| Antiandrogen Withdrawal Response | |||||
| No | 19 (63%) | 85 (79%) | 92 (75%) | 18 (56%) | 195 (74%) |
| Yes | 11 (37%) | 23 (21%) | 31 (25%) | 14 (44%) | 68 (26%) |
| Characeristics at Time of Chemotherapy Consideration | |||||
| ECOG Performance Status† | |||||
| 0-1 | 27 (96%) | 83 (72%) | 91 (69%) | 16 (53%) | 217 (71%) |
| 2 | 1 (4%) | 26 (22%) | 29 (22%) | 3 (10%) | 59 (19%) |
| 3-4 | 0 (0%) | 7 (6%) | 12 (9%) | 11 (37%) | 30 (10%) |
| PSA Doubling Time† | |||||
| 0-30 | 9 (32%) | 30 (26%) | 28 (21%) | 3 (9%) | 70 (23%) |
| ≥30-60 | 6 (21%) | 46 (40%) | 38 (29%) | 13 (38%) | 103 (33%) |
| ≥60 | 13 (46%) | 39 (34%) | 67 (50%) | 18 (53%) | 137 (44%) |
| Median PSA (mg/dL) | 113 | 158 | 131 | 154 | 146 |
| Median LDH (IU/L) | 236 | 244 | 223 | 208 | 223 |
| Median ALP (IU/L) | 161 | 149 | 144 | 123 | 144 |
| Median Hgb (g/L) | 124 | 120 | 120 | 115 | 120 |
| Chemotherapy† | |||||
| Docetaxel | 11 (37%) | 30 (26%) | 29 (20%) | 5 (15%) | 75 (23%) |
| Mitoxantrone | 6 (20%) | 27 (23%) | 47 (33%) | 12 (35%) | 92 (29%) |
| Docetaxel and Mitoxantrone | 8 (27%) | 37 (32%) | 29 (20%) | 0 (0%) | 74 (23%) |
| None | 5 (17%) | 20 (17%) | 37 (26%) | 17 (50%) | 79 (25%) |
| Other | 0 (0%) | 2 (2%) | 0 (0%) | 0 (0%) | 2 (<1%) |
Abbreviations: PSA, prostate specific antigen; Dx, diagnosis; RT, radiotherapy; CCI, Charleston comorbidity index, CRPC, castration resistant prostate cancer; ADT, androgen deprivation therapy; ECOG, Eastern Cooperative Oncology Group; LDH, lactose dehydrogenase; ALP, alkaline phosphatase; Hgb, hemoglobin (†, meets p<0.05 statistical significance per Fisher's Exact Test or Chi-squared test).